Literature DB >> 3096918

An in vitro and in vivo screening system for new hypoxic cell radiosensitizers using EMT6 cells.

Y Shibamoto, K Ono, M Takahashi, E Kano, H Hori, T Shibata, S Inayama, M Abe.   

Abstract

An experimental tumor system consisting of single cells, spheroids, and solid tumors was developed using the EMT6/KU cell-line for evaluation of new hypoxic cell sensitizers. This paper describes the radiation dose-survival curves of the system and the effects of four sensitizers [misonidazole, Ro 03-8799, KB-11 (a sulfonyltetrazole derivative), and DNIE (a dinitroimidazole derivative)] in this system. Dose-survival curves of the spheroids varied significantly depending on the irradiation conditions, but it was found that the spheroids could model the solid tumors when they were irradiated in flat-bottomed flasks. These spheroids and solid tumors contained substantial fractions of hypoxic cells, and hence were suitable for testing hypoxic cell sensitizers. Misonidazole at a concentration of 1 mM or 1 mmol/kg showed a constant enhancement ratio (ER) of 1.55 in all of the systems. The ERs of the other three compounds for single cells, spheroids, and solid tumors were 2.1, 1.9, and 1.65, respectively, for Ro 03-8799 (1 mM or 1 mmol/kg); 2.6, 1.6, and 1.0, respectively, for KB-11 (0.5mM or 0.5 mmol/kg); 1.8, 1.2, and 1.1, respectively, for DNIE (0.5mM or 0.5 mmol/kg). These results indicated that the ER for spheroids is closer to the ER for solid tumors than is the ER for single cells in most cases. It was also suggested that an efficient sensitizer in vivo shows little or no difference between its ER for single cells and that for spheroids.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096918

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  5 in total

1.  KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

Authors:  K Sasai; Y Shibamoto; M Takahashi; L Zhou; H Hori; H Nagasawa; T Shibata; S Inayama; M Abe
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety.

Authors:  Yoshihiro Uto; Hideko Nagasawa; Cheng-Zhe Jin; Shinichi Nakayama; Ayako Tanaka; Saori Kiyoi; Hitomi Nakashima; Mariko Shimamura; Seiichi Inayama; Tomoya Fujiwara; Yoshio Takeuchi; Yoshimasa Uehara; Kenneth L Kirk; Eiji Nakata; Hitoshi Hori
Journal:  Bioorg Med Chem       Date:  2008-04-24       Impact factor: 3.641

3.  In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine.

Authors:  M Langenbacher; R J Abdel-Jalil; W Voelter; M Weinmann; S M Huber
Journal:  Strahlenther Onkol       Date:  2013-01-31       Impact factor: 3.621

4.  Detection of hypoxic cells in murine tumors using the comet assay: comparison with a conventional radiobiological assay.

Authors:  K Shibuya; K Sasai; X Xie; H Utsumi; T Shibata; M Hiraoka
Journal:  Jpn J Cancer Res       Date:  1999-08

5.  A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.

Authors:  K Sasai; Y Shibamoto; M Takahashi; M Abe; J Wang; L Zhou; S Nishimoto; T Kagiya
Journal:  Jpn J Cancer Res       Date:  1989-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.